Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
Klaria Pharma Holding AB (publ.) functions as a pharmaceutical enterprise, active both in Sweden and across global territories. Its current portfolio features Sumatriptan for migraine management and Midazolam for combating acute epileptic seizures. Within its pipeline, Klaria is developing Epinephrine/Adrenaline to address severe allergic responses, Naloxone for reversing opioid overdoses, and Ketamine for applications in acute pain and mood disorders. Moreover, the company is actively involved in bringing cannabis/cannabinoid products, including THC and CBD, to market for medical and recreational purposes. Established in 2014, Klaria is headquartered in Uppsala, Sweden.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is reasonably priced on P/E.
Target Price
The average target price of KLAR.ST is 1.00 and suggests 21% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc